Global /Sweden /Healthcare /Drug Manufacturers - General /GUARD

Guard Therapeutics International AB (publ)

GUARD

• STO: GUARD • Delayed

1.03SEK 0.4%

0.1087 USD

As of 11 June 2026, Guard Therapeutics International AB (publ) has a market cap of $2.18M USD, ranking #47002 globally and #816 in Sweden. It ranks #4162 in the Healthcare sector, and #1318 in the Drug Manufacturers - General industry.

Global Rank

47002

Country Rank

816

Sector Rank

4162

Industry Rank

1318

Key Stats

Market Cap

$2.18MUSD

20.65M SEK

Enterprise Value

-$3.08MUSD

-29.17M SEK

Net Income (TTM)

-$11.46MUSD

-108.85M SEK

Forward PE

0.4

PB Ratio

0.5

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Tobias Agervald open_in_new

Employees

Founded

2008

Website

guardtherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.4%	-13%	-30%	-44%	-50%	-30%	-92%	-83%	-99%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	GUARD Guard Therapeutics International AB ISIN: SE0021181559 Shares Out.: Shares Outstanding: 20.168M¹ TV: TradingView: OMXSTO: GUARD SA: Stock Analysis: STO: GUARD YF: Yahoo Finance: GUARD.ST GF: Google Finance: STO: GUARD BA: Barron's: GUARD MS: Morningstar: XSTO: GUARD	1.03 SEK	TV: TradingView: OMXSTO: GUARD SA: Stock Analysis: STO: GUARD YF: Yahoo Finance: GUARD.ST GF: Google Finance: STO: GUARD BA: Barron's: GUARD MS: Morningstar: XSTO: GUARD

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabetes, heart failure, alport syndrome, sickle-cell nephropathy, and preeclampsia. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.69B 139.44B SEK 675K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.3B 31.37B SEK 152K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.9B 27.5B SEK 133K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$446.11M 4.24B SEK 20K%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$297.1M 2.82B SEK 14K%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$290.24M 2.76B SEK 13K%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 35M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 25M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 17M%	97.4	United States
Roche Holding AG SIX: RO	$320.56B 256.25B CHF 15M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.45B 215.59B GBP 13M%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 13M%	15.1	United States

chevron_leftBack